Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

BACKGROUND: DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity. METHODS: Healthy participants aged 18–55...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Infect Dis
Main Authors: McCarthy, James S, Lotharius, Julie, Rückle, Thomas, Chalon, Stephan, Phillips, Margaret A, Elliott, Suzanne, Sekuloski, Silvana, Griffin, Paul, Ng, Caroline L, Fidock, David A, Marquart, Louise, Williams, Noelle S, Gobeau, Nathalie, Bebrevska, Lidiya, Rosario, Maria, Marsh, Kennan, Möhrle, Jörg J
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Science ;, The Lancet Pub. Group 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5446412/
https://ncbi.nlm.nih.gov/pubmed/28363636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(17)30171-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados